Wilsey Michael J, Baran Jessica V, Lamos Luke, Beacker Jesse, Florio Jared, Oliveros Lea, Sriaroon Panida, Brown Jerry M, Vanderhoof Jon A
Department of Pediatrics, University of South Florida Morsani College of Medicine, Tampa, FL, United States.
Pediatric Gastroenterology, Hepatology, and Nutrition of Florida, St. Petersburg, FL, United States.
Front Nutr. 2023 Jun 20;10:1208334. doi: 10.3389/fnut.2023.1208334. eCollection 2023.
Cow's milk protein allergy (CMPA) occurs commonly in infants. While the long-term efficacy of amino acid formulas for managing CMPA is well-established, there is limited data on the short-term symptom improvement of using amino acid formula (AAF).
This study aimed to determine the short-term effects of managing suspected CMPA in infants aged 6 months and under using a commercial AAF.
Healthcare providers who treated infants with suspected CMPA aged 6 months or younger ( = 104) provided de-identified survey data in this prospective study. Healthcare providers scored symptoms for severity from 0 to 3 (none, low, moderate, severe) before using a commercial AAF at Visit 1 and at Visit 2 (3-6 weeks later).
Gastrointestinal (94%), skin (87%), respiratory (86%), and uncategorized symptoms (89%) improved from AAF initiation, and these findings were consistent across different follow-up visit durations.
This study is the most extensive prospective analysis conducted in the United States examining the short-term change in suspected CMPA symptoms using an AAF. These findings suggest that AAF may decrease the severity of suspected CMPA symptoms in infants 6 months or younger, often by the next follow-up visit. Further randomized controlled trials are required to confirm these initial findings.
牛奶蛋白过敏(CMPA)在婴儿中很常见。虽然氨基酸配方奶粉治疗CMPA的长期疗效已得到充分证实,但关于使用氨基酸配方奶粉(AAF)的短期症状改善的数据有限。
本研究旨在确定使用市售AAF治疗6个月及以下疑似CMPA婴儿的短期效果。
在这项前瞻性研究中,治疗6个月及以下疑似CMPA婴儿(n = 104)的医疗保健提供者提供了去识别化的调查数据。医疗保健提供者在第1次就诊时(使用市售AAF之前)和第2次就诊时(3 - 6周后)对症状严重程度进行评分,范围为0至3(无、轻度、中度、重度)。
从开始使用AAF起,胃肠道症状(94%)、皮肤症状(87%)、呼吸道症状(86%)和未分类症状(89%)均有所改善,且这些结果在不同的随访时间内是一致的。
本研究是美国进行的最广泛的前瞻性分析,研究了使用AAF时疑似CMPA症状的短期变化。这些发现表明,AAF可能会降低6个月及以下婴儿疑似CMPA症状的严重程度,通常在下一次随访时即可显现。需要进一步的随机对照试验来证实这些初步发现。